Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Prostate Cancer Excellence Forum

Prostate Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Alexandra Sokolova video thumbnail.
Videos
Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024
02/15/2024

Featuring Alexandra Sokolova, MD

Featuring Alexandra Sokolova, MD ...
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares...
02/15/2024
Journal of Clinical Pathways
News
A Look at the Updates in the NCCN Clinical Practice Guidelines For Prostate Cancer
02/09/2024

By Emry Lloyd

By Emry Lloyd
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in...
02/09/2024
Journal of Clinical Pathways
Neal Shore, MD, FACS.
Videos
Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study
01/18/2024

Featuring Neal Shore, MD, FACS

Featuring Neal Shore, MD, FACS ...
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses...
01/18/2024
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Atish Choudhury, MD, PhD, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Genetically Unselected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss treatment modalities that have demonstrated survival benefit in metastatic castration-resistant prostate cancer for genetically unselected patients.
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss treatment modalities that have demonstrated survival benefit in metastatic castration-resistant prostate cancer for genetically unselected patients.
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Real-World Impact of Leuprolide Acetate Late Dosing on Testosterone Suppression for Prostate Cancer
Videos
Real-World Impact of Leuprolide Acetate Late Dosing on Testosterone Suppression for Prostate Cancer
05/04/2021
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses...
05/04/2021
Journal of Clinical Pathways
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
Videos
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
04/23/2021
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses...
04/23/2021
Journal of Clinical Pathways
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
Videos
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
04/21/2021
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH,...
04/21/2021
Journal of Clinical Pathways
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
Videos
Abiraterone vs Docetaxel for De Novo Prostate Cancer in Real-World and Trial Settings
03/18/2021
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses results from a study which compared real-world survival among men with de novo metastatic prostate cancer treated with abiraterone acetate or docetaxel and compared these outcomes to those seen in clinical...
Daniel Geynisman, MD, discusses...
03/18/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement